Please join us for our fourth quarterly call and year end update of 2017 on April 5, 2018 at 4:30pm.
TapImmune President and CEO, Peter Hoang, to present at 2018 The Microcap Conference.
TapImmune’s cancer vaccine significantly extended progression free survival of ovarian cancer patients, as compared to the current standard of care.
An investigational vaccine called TPIV200 was found to be safe and generated strong T-cell immunity against tumor cells, significantly delaying recurrence in breast and ovarian cancer patients who had achieved complete responses in a Phase 1 trial.
TapImmune released some interesting results this week from a Phase I trial conducted at the Mayo Clinic that will add some spice to that discussion.
TPIV200 vaccine candidate showed 90% of patients developed robust and durable antigen-specific immune responses against FRa.
The publication of clinical data from a Phase 1 trial of TPIV200, the company’s multi-epitope T-cell vaccine targeting Folate Receptor Alpha in patients with ovarian and breast cancer will be available online today.
TapImmune President & CEO, Peter Hoang, will be participating in two conferences next week.